Olympus Grabs FDA’s De Novo Status for BPH Treatment

April 8, 2020

Olympus’ iTind, a nonsurgical device for treating benign prostatic hyperplasia (BPH), has received a de novo classification from the FDA.

The agency grants the designation for novel devices with no existing classification or predicate device on the market.

The iTind is a nonsurgical, minimally invasive device that expands over five days to reshape the prostate and allow urine to flow.

BPH, or prostate gland enlargement, is a common disease in older men that frequently causes lower urinary tract symptoms.

View today's stories